A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)

Organon

Status and phase: Completed; Phase 3

Conditions: Osteoporosis, Postmenopausal

Treatments: Drug: Comparator: risedronate / Duration of Intervention: 12 mo; Drug: MK0217, alendronate sodium/Duration of Intervention: 12 mo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092040

0217-907

2004_019

Details and patient eligibility

About

The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.

Enrollment: 936 patients

Sex: Female

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal women with osteoporosis

Exclusion criteria

• Any known allergy to the study drug

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind